EDGAR·FLOW

Bluejay Diagnostics, Inc. — Form 8-K

Filed November 13, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Bluejay Diagnostics completed enrollment of 777 patients in its SYMON-II pivotal study (exceeding 750-patient target), with preliminary data showing 18% 28-day mortality. The company established an alternative manufacturing facility through Sanyoseiko ahead of the October 23, 2026 contractual deadline with Toray Industries and secured a distribution agreement with Lovell Government Services. As of September 30, 2026, Bluejay held $7.38M in cash (vs. $5.16M at year-end 2025), burned $5.09M in nine-month operating losses, and estimates runway through Q2 2027; FDA 510(k) submission is targeted for H1 2027.
Why this rating

Multiple critical de-risking milestones—study enrollment, manufacturing redundancy, distribution deal—directly support path to FDA submission and commercialization. Relative to $2.6M market cap, the $7.38M cash position (2.8× market cap) and reduced runway risk are material. Near-term catalysts align favorably.

Tradability signal
NO TRADE

No trade: positive news with only +2.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.61 ▼ 0.00%
at our read · unknown
$2.61
+10 min · unknown
$2.68 ▲ 2.68%
+30 min · unknown
$2.68 ▲ 2.68%
+1 hr · unknown
$2.29 ▼ 12.07%
+4 hrs · unknown
$2.28 ▼ 12.64%

The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ BJDX · stock on Yahoo Finance ↗

See more from November 13, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.